Business Wire

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

7.9.2023 10:00:00 EEST | Business Wire | Press release

Share

Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/

CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.

Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.

CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.

Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.

CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.

Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.

Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

About Cerba HealthCare

Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.

Cerba HealthCare, enlightening health.

Additional information is available at www.cerbahealthcare.com

About Cerba Research

We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.​

We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.​

Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.

For more information visit www.cerbaresearch.com

About CIRION

CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).

Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts:

Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com

CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn29.4.2026 21:25:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced its financial results for the first quarter of 2026, reporting a net profit of QAR 333 million, marking a significant 97% increase compared to the same period last year. The results underscore the strength of the Company’s operating model and the successful execution of its expansion strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429718889/en/ Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn (Photo: AETOSWire) The company recorded revenues of QAR 1.455 billion, up from QAR 1.309 billion in Q1 2025. Gross profit rose to QAR 561 million compared to QAR 416 million, representing a year-on-year increase of 35%. EBITDA grew by 73% to reach QAR 473 million, while earnings per share increased by 90% to QAR 0.089. These results reflect comprehensive growth across all key financial indicators, supported by a clear investment vision and the Company’s abili

DC Secretary Announces Annual Determinations Committees Outcome29.4.2026 16:36:00 EEST | Press release

DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 29, 2026. Global Dealer Voting Members (for all Regions): Non-Dealer Voting Members (for all Regions): Bank of America, N.A. Citadel Americas LLC Barclays Bank plc Elliott Investment Management L.P. BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Regional Dealer Voting Member for the Americas, EMEA, Asia Ex-Japan, and Japan Determination Committees: CCP Members for the Americas, EMEA, Asia Ex-Japan, and Australia-New Zealand Determinations Committees: Mizuho Securities Co., Ltd. ICE Clear Credit LLC LCH S.A. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommitte

Boomi Builds Analyst Momentum Across Integration, API Management, Data Management, and Agentic AI29.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced continued analyst recognition across multiple strategic technology categories, underscoring the company’s momentum as enterprises look for a unified foundation to connect data, applications, APIs, automation, and AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429987428/en/ Boomi Builds Analyst Momentum Across Integration, API Management, Data Management, and Agentic AI Over the past several months, Boomi has been recognized across integration, API management, data management, and agentic AI-related categories. The company was named a Leader and positioned highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service, marking Boomi’s 12th consecutive year as a Leader. Boomi was also named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment (doc #US52034025, March 2026) and was recognized as a Cha

CSC Urges Enterprises Evaluate Applying for .BRAND Domains to Navigate AI-Driven Domain Threats and Opportunities29.4.2026 16:00:00 EEST | Press release

CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today announced a new program to coincide with ICANN’s new Generic Top-Level Domain (gTLD) application window and to support enterprises submitting a .BRAND TLD application between April 30 and August 12, 2026. Owning a .BRAND domain gives an organization exclusive control over its entire domain infrastructure, mitigating third-party lookalike domain registrations that lead to phishing and domain spoofing. This will be the first time ICANN has opened applications for new gTLDs, including .BRANDs, since the inaugural round in 2012. There is no known date for a third window opening. As the largest provider of these domain services globally, CSC manages more than one-third (160+) of all .BRANDs, helping to secure many of the world’s most recognizable brands. Since the round one application window closed in 2012, CSC has provided continuous .BRAND registry ma

Driscoll's Names Wyard Stomp Chief Operating Officer and Expands Shaily Sanghvi's Role to Lead Global Strategy29.4.2026 16:00:00 EEST | Press release

Driscoll's, the world's leading berry brand, today announced two leadership appointments to support CEO Soren Bjorn's long-term strategy to scale the company's proven, flavor-first business model globally, bringing the same deliberate approach that made Driscoll's the #2 retail food and beverage brand in the United States to consumers in every market the company serves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429432633/en/ Wyard Stomp has been appointed Chief Operating Officer (COO), a newly created role, while continuing to lead Driscoll's Europe, Middle East, and Africa (EMEA) business. As COO, Stomp will partner closely with the Executive Leadership Team to turn strategy into action, lead cross-functional initiatives, and ensure the company executes at the pace required to support its global growth ambitions. Stomp joined Driscoll's in 2012 and has held several senior leadership roles in Europe and the United St

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye